Treatment Strategies for KRAS Mutated Non-small Cell Lung Cancer

Joan H. Schiller, Sudeshna Adak, Richard H. Feins, Steven M. Keller, Willard A. Fry, Robert B. Livingston, M. Elizabeth M. Hammond, Barbara Wolf, Linda Sabatini, James Jett, Leslie Kohman, David H. Johnson, Lack of Prognostic Significance of p53 and K-ras Mutations in Primary Resected Non–Small-Cell Lung Cancer on E4592: A Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy Journal of Clinical Oncology. ,vol. 19, pp. 448- 457 ,(2001) , 10.1200/JCO.2001.19.2.448

M Paesmans, J P Sculier, P Libert, G Bureau, G Dabouis, J Thiriaux, J Michel, O Van Cutsem, R Sergysels, P Mommen, Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. Journal of Clinical Oncology. ,vol. 13, pp. 1221- 1230 ,(1995) , 10.1200/JCO.1995.13.5.1221

Marta Puyol, Alberto Martín, Pierre Dubus, Francisca Mulero, Pilar Pizcueta, Gulfaraz Khan, Carmen Guerra, David Santamaría, Mariano Barbacid, A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma Cancer Cell. ,vol. 18, pp. 63- 73 ,(2010) , 10.1016/J.CCR.2010.05.025

Charles A. Butts, Keyue Ding, Lesley Seymour, Philip Twumasi-Ankrah, Barbara Graham, David Gandara, David H. Johnson, Kenneth A. Kesler, Mark Green, Mark Vincent, Yvon Cormier, Glenwood Goss, Brian Findlay, Michael Johnston, Ming-Sound Tsao, Frances A. Shepherd, Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non–Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10 Journal of Clinical Oncology. ,vol. 28, pp. 29- 34 ,(2010) , 10.1200/JCO.2009.24.0333

Sjoerd Rodenhuis, Robert J. C. Slebos, TherasOncogenes in Human Lung Cancer American Review of Respiratory Disease. ,vol. 142, pp. S27- S30 ,(1990) , 10.1164/AJRCCM/142.6_PT_2.S27

Daquan Meng, Mingli Yuan, Xiaojuan Li, Lijun Chen, Jie Yang, Xin Zhao, Wanli Ma, Jianbao Xin, Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis. Lung Cancer. ,vol. 81, pp. 1- 10 ,(2013) , 10.1016/J.LUNGCAN.2013.03.019

Gregory J. Riely, Melissa L. Johnson, Chanoa Medina, Naiyer A. Rizvi, Vincent A. Miller, Mark G. Kris, M. Catherine Pietanza, Christopher G. Azzoli, Lee M. Krug, William Pao, Michelle S. Ginsberg, A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations Journal of Thoracic Oncology. ,vol. 6, pp. 1435- 1437 ,(2011) , 10.1097/JTO.0B013E318223C099

C Mascaux, N Iannino, B Martin, M Paesmans, T Berghmans, M Dusart, A Haller, P Lothaire, A-P Meert, S Noel, J-J Lafitte, J-P Sculier, The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis British Journal of Cancer. ,vol. 92, pp. 131- 139 ,(2005) , 10.1038/SJ.BJC.6602258

Gregory J. Riely, Mark G. Kris, Daniel Rosenbaum, Jenifer Marks, Allan Li, Dhananjay A. Chitale, Khedoudja Nafa, Elyn R. Riedel, Meier Hsu, William Pao, Vincent A. Miller, Marc Ladanyi, Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clinical Cancer Research. ,vol. 14, pp. 5731- 5734 ,(2008) , 10.1158/1078-0432.CCR-08-0646

B. Johnson, V. Miller, L. Amler, H. Stern, C. Soh, P. O'Connor, F. Kabbinavar, 8LBA Biomarker evaluation in the randomized, double-blind, placebo-controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) Ejc Supplements. ,vol. 7, pp. 5- 6 ,(2009) , 10.1016/S1359-6349(09)72037-3